Table 5.

Association between the duration/timing of thymosin α1 use and non-recovery rate.

Duration of thymosin α1 use (days)	ORs	95% CI	p	Timing of thymosin α1 use (days)	ORs	95% CI	p
Model 1				Model 1
Continuous variable (n = 306)	1.0	0.9–1.1	0.481	Continuous variable (n = 306)	1.1	1.0–1.2	<0.001
Model 2 (median value)				Model 2 (median value)
≤5 (n = 172)	Ref.			≤3 (n = 159)	Ref.
>5 (n = 134)	1.3	0.7–2.1	0.404	>3 (n = 147)	2.4	1.3–4.6	0.007
Model 3 (tertile analysis) (p for trend: 0.574)				Model 3 (tertile analysis) (p for trend: 0.005)
≤3 (n = 106)	Ref.			≤1 (n = 109)	Ref.
3–7 (n = 103)	0.4	0.2–0.9	0.037	2–10 (n = 91)	4.1	1.5–10.7	0.004
≥7 (n = 97)	1.2	0.6–2.5	0.648	≥10 (n = 106)	6.2	2.5–15.3	<0.001

All models were adjusted for age, diabetes, PaO2/FiO2, lymphocyte and platelet count, serum creatinine level.

ORs, odds ratios.